Exelixis: Wide Efficacy Benefits in Phase 3 Renal Cell Carcinoma Trial of Combo

 – Efficacy benefits with recently approved combination regimen observed regardless of baseline International Metastatic Renal Cell Carcinoma Database Consortium risk status, organ site of metastases or extent of tumor burden –

– Data to be presented during the 2021 American Society of Clinical Oncology’s Annual Meeting –

https://www.biospace.com/article/releases/exelixis-announces-consistent-efficacy-benefits-across-subgroups-of-phase-3-checkmate-9er-trial-of-cabometyx-cabozantinib-in-combination-with-opdivo-nivolumab-as-a-first-line-treatment-for-patients-with-advanced-renal-cell-carcinoma/